Correspondence 0001193125-23-286835 from Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687) (RNAC)
Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)
Date: Dec. 1, 2023 · CIK: 0001453687 · Accession: 0001193125-23-286835
AI Filing Summary & Sentiment
File numbers found in text: 333-275171
Letter
Re: Cartesian Therapeutics, Inc.
December 1, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tamika Sheppard
Registration Statement Filed on Form S-3, as amended on December 1, 2023 (the “Registration Statement”)
File No. 333-275171
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 5:00 p.m., Eastern Time, on December 1, 2023 or as soon as practicable thereafter.
Please contact Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 or brosenzweig@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Rosenzweig by telephone when this request for acceleration has been granted.
Respectfully,
Cartesian Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 1, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Cartesian Therapeutics, Inc. Registration Statement Filed on Form S-3, as amended on December 1, 2023 (the “Registration Statement”) File No. 333-275171 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 5:00 p.m., Eastern Time, on December 1, 2023 or as soon as practicable thereafter. Please contact Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 or brosenzweig@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Rosenzweig by telephone when this request for acceleration has been granted. Respectfully, Cartesian Therapeutics, Inc. By: /s/ Carsten Brunn, Ph.D. Name: Carsten Brunn, Ph.D. Title: President and Chief Executive Officer cc: Brian K. Rosenzweig, Covington & Burling LLP